Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for CML patients: trial tests potential Game-Changer drug

NCT ID NCT04971226

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is testing a new oral medication called asciminib against standard first-line treatments for adults newly diagnosed with a specific type of chronic myeloid leukemia (CML). The goal is to see if asciminib is more effective at controlling the disease and if patients can safely stop treatment after several years if they achieve a deep, sustained response. About 406 participants will be randomly assigned to receive either asciminib or one of the standard drugs chosen by their doctor.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA (CML) PHILADELPHIA CHROMOSOME POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Avera Cancer

    Sioux Falls, South Dakota, 57105, United States

  • Chattanooga Onc And Hem Assoc PC

    Chattanooga, Tennessee, 37404, United States

  • Florida Cancer Specialists

    Fort Myers, Florida, 33901, United States

  • Florida Cancer Specialists Pan

    Tallahassee, Florida, 32308, United States

  • Novartis Investigative Site

    Kingswood, New South Wales, 2747, Australia

  • Novartis Investigative Site

    Port Macquarie, New South Wales, 2444, Australia

  • Novartis Investigative Site

    Adelaide, South Australia, 5000, Australia

  • Novartis Investigative Site

    Southport, 4215, Australia

  • Novartis Investigative Site

    Linz, Upper Austria, 4010, Austria

  • Novartis Investigative Site

    Leuven, Vlaams Brabant, 3000, Belgium

  • Novartis Investigative Site

    Brussels, 1000, Belgium

  • Novartis Investigative Site

    Varna, 9010, Bulgaria

  • Novartis Investigative Site

    Calgary, Alberta, T2N 5G2, Canada

  • Novartis Investigative Site

    Hamilton, Ontario, L8V 1C3, Canada

  • Novartis Investigative Site

    Ottawa, Ontario, K1H 8L6, Canada

  • Novartis Investigative Site

    Toronto, Ontario, M5G 2M9, Canada

  • Novartis Investigative Site

    Guangzhou, Guangdong, 510515, China

  • Novartis Investigative Site

    Shenzhen, Guangdong, 518037, China

  • Novartis Investigative Site

    Zhengzhou, Henan, 450008, China

  • Novartis Investigative Site

    Wuhan, Hubei, 430022, China

  • Novartis Investigative Site

    Nanjing, Jiangsu, 210000, China

  • Novartis Investigative Site

    Suzhou, Jiangsu, 215004, China

  • Novartis Investigative Site

    Xian, Shanxi, 710068, China

  • Novartis Investigative Site

    Chengdu, Sichuan, 610041, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, 310003, China

  • Novartis Investigative Site

    Wenzhou, Zhejiang, 325000, China

  • Novartis Investigative Site

    Beijing, 100044, China

  • Novartis Investigative Site

    Beijing, 100730, China

  • Novartis Investigative Site

    Lanzhou, 730000, China

  • Novartis Investigative Site

    Tianjin, 300020, China

  • Novartis Investigative Site

    Ostrava, Poruba, 708 52, Czechia

  • Novartis Investigative Site

    Brno, 625 00, Czechia

  • Novartis Investigative Site

    Hradec Králové, 500 05, Czechia

  • Novartis Investigative Site

    Aarhus N, 8200, Denmark

  • Novartis Investigative Site

    Copenhagen, DK-2100, Denmark

  • Novartis Investigative Site

    Helsinki, FIN 00290, Finland

  • Novartis Investigative Site

    Bordeaux, 33076, France

  • Novartis Investigative Site

    Lyon, 69373, France

  • Novartis Investigative Site

    Nantes, 44093, France

  • Novartis Investigative Site

    Paris, 75475, France

  • Novartis Investigative Site

    Mannheim, Baden-Wurttemberg, 68305, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, 60590, Germany

  • Novartis Investigative Site

    Jena, Thuringia, 07740, Germany

  • Novartis Investigative Site

    Aachen, 52074, Germany

  • Novartis Investigative Site

    Berlin, 13353, Germany

  • Novartis Investigative Site

    Lübeck, 23538, Germany

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, 4032, Hungary

  • Novartis Investigative Site

    Kaposvár, 7400, Hungary

  • Novartis Investigative Site

    Kecskemét, 6001, Hungary

  • Novartis Investigative Site

    Delhi, 110085, India

  • Novartis Investigative Site

    Petah Tikva, 4941492, Israel

  • Novartis Investigative Site

    Ramat Gan, 5265601, Israel

  • Novartis Investigative Site

    Tel Aviv, 6423906, Israel

  • Novartis Investigative Site

    Bologna, BO, 40138, Italy

  • Novartis Investigative Site

    Milan, MI, 20122, Italy

  • Novartis Investigative Site

    Reggio Emilia, RE, 42123, Italy

  • Novartis Investigative Site

    Roma, RM, 00161, Italy

  • Novartis Investigative Site

    Verona, VR, 37134, Italy

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 453-8511, Japan

  • Novartis Investigative Site

    Toyoake, Aichi-ken, 4701192, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 0608648, Japan

  • Novartis Investigative Site

    Kobe, Hyōgo, 6500047, Japan

  • Novartis Investigative Site

    Kurashiki, Okayama-ken, 7108602, Japan

  • Novartis Investigative Site

    Sakai, Osaka, 590-0197, Japan

  • Novartis Investigative Site

    Suita, Osaka, 5650871, Japan

  • Novartis Investigative Site

    Shimotsuke, Tochigi, 329-0498, Japan

  • Novartis Investigative Site

    Chūō, Yamanashi, 409-3898, Japan

  • Novartis Investigative Site

    Akita, 010-8543, Japan

  • Novartis Investigative Site

    Fukuoka, 8128582, Japan

  • Novartis Investigative Site

    Fukushima, 9601295, Japan

  • Novartis Investigative Site

    Osaka, 5458586, Japan

  • Novartis Investigative Site

    Yamagata, 990 9585, Japan

  • Novartis Investigative Site

    Kuantan, Pahang, 25100, Malaysia

  • Novartis Investigative Site

    George Town, Pulau Pinang, 10450, Malaysia

  • Novartis Investigative Site

    Subang Jaya, Selangor, 47500, Malaysia

  • Novartis Investigative Site

    Kuala Selangor, 68000, Malaysia

  • Novartis Investigative Site

    Amsterdam, North Holland, 1081 HV, Netherlands

  • Novartis Investigative Site

    Bergen, NO-5021, Norway

  • Novartis Investigative Site

    Oslo, 0372, Norway

  • Novartis Investigative Site

    Porto, 4200-072, Portugal

  • Novartis Investigative Site

    Vila Nova de Gaia, 4434 502, Portugal

  • Novartis Investigative Site

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    Singapore, 169608, Singapore

  • Novartis Investigative Site

    Košice, 041 90, Slovakia

  • Novartis Investigative Site

    Uijeongbu-si, Gyeonggi-do, 11759, South Korea

  • Novartis Investigative Site

    Seoul, Korea, 03080, South Korea

  • Novartis Investigative Site

    Seoul, 06351, South Korea

  • Novartis Investigative Site

    Seoul, 06591, South Korea

  • Novartis Investigative Site

    Granada, Andalusia, 18014, Spain

  • Novartis Investigative Site

    El Palmar, Murcia, 30120, Spain

  • Novartis Investigative Site

    Pamplona, Navarre, 31008, Spain

  • Novartis Investigative Site

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    Madrid, 28046, Spain

  • Novartis Investigative Site

    Gothenburg, 413 45, Sweden

  • Novartis Investigative Site

    Lund, 221 85, Sweden

  • Novartis Investigative Site

    Stockholm, 141 86, Sweden

  • Novartis Investigative Site

    Bellinzona, 6850, Switzerland

  • Novartis Investigative Site

    Taichung, 40447, Taiwan

  • Novartis Investigative Site

    London, W12 0HS, United Kingdom

  • Novartis Investigative Site

    Nottingham, NG5 1PB, United Kingdom

  • Novartis Investigative Site

    Oxford, OX3 7LE, United Kingdom

  • Oregon Health Sciences University

    Portland, Oregon, 97239, United States

  • Rocky Mountain Cancer Centers

    Denver, Colorado, 80218, United States

  • Texas Oncology

    Dallas, Texas, 75246, United States

  • Texas Oncology

    Dallas, Texas, 75251, United States

  • Texas Oncology-Baylor USO

    Dallas, Texas, 75246, United States

  • Uni of Massachusetts Medical Center

    Worcester, Massachusetts, 01655, United States

  • University of Kentucky

    Lexington, Kentucky, 40536, United States

  • Wake Forest University Baptist Medical Center

    Winston-Salem, North Carolina, 27157, United States

  • Williamette Cancer Center

    Eugene, Oregon, 97401, United States

Conditions

Explore the condition pages connected to this study.

CHRONIC MYELOID LEUKEMIA (CML) PHILADELPHIA CHROMOSOME POSITIVE